<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00689780</url>
  </required_header>
  <id_info>
    <org_study_id>D3120C00003</org_study_id>
    <nct_id>NCT00689780</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Safety, Tolerability and Pharmacokinetics of AZD1940</brief_title>
  <official_title>A Phase I, Multi-Centre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of AZD1940, Including an Interaction Study, After Administration of Oral Multiple Ascending Doses in Adult Subjects With Chronic Low Back Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I, Multi-Centre, Randomised, Double-blind, Placebo-controlled Study to Investigate
      the Safety, Tolerability and Pharmacokinetics of AZD1940, Including an Interaction Study,
      After Administration of Oral Multiple Ascending Doses in Adult Subjects with Chronic Low Back
      Pain
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of adverse events (AEs) occurring during the study, blood pressure (supine and standing), pulse rate, respiratory rate, body temperature, laboratory variables and ECG</measure>
    <time_frame>Vital signs, laboratory variables and adverse event each day throughout the study Paper printout ECG and/or digital ECG throughout the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of psychometric rating scales ( VAMS, CDR test battery, DEQ, ARCI and Bond-Lader)</measure>
    <time_frame>Psychometric tests and VAMS (Visual Analogue Mood Scale) throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate the PK profile (including dose proportionality) of AZD1940 by assessment of plasma concentrations</measure>
    <time_frame>Bloodsampling Day 1,6, 10 and 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma levels of midazolam and 4ß hydroxycholesterol and 6β hydroxycortisol:cortisol urine excretion ratio as markers</measure>
    <time_frame>Bloodsampling at day -1, 14</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Low Back Pain</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD1940 + Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1940</intervention_name>
    <description>Oral solution Multiple ascending dose given orally once daily at day 1-12</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Oral solution given orally once daily on day -1 and day 14</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A diagnosis of Chronic Low Back Pain according to Quebec Task force Class 1-3 and an
             average pain intensity score of 3-9 on NRS(0-10) during the past week.

          -  Clinical normal physical findings, including blood pressure, pulse rate &gt; 45bpm, ECG
             (with normal QTcF interval &lt;450msec and without any additional risk factors for
             Torsades de Pointes) and laboratory assessments, as judged by investigator

          -  Body Mass Index (BMI) ≥18 to ≤32 kg/m2 inclusive and body weight ≥50 to ≤100 kg

        Exclusion Criteria:

          -  History of somatic disease/condition which may interfere with the objectives of the
             study, with the exception of Chronic Low Back Pain

          -  History of previous or ongoing psychiatric disease/condition including psychosis,
             affective disorder, anxiety disorder, borderline state and personality disorder

          -  Clinically significant illness with the exception of Chronic Low Back Pain
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janet Post</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca R&amp;D SödertäljeSE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wolfgang Kühn</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles AB Phase 1 Services Strandbodgatan Uppsala, Sweden+</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Linkoping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lulea</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Upssala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2008</study_first_submitted>
  <study_first_submitted_qc>June 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2008</study_first_posted>
  <last_update_submitted>December 8, 2010</last_update_submitted>
  <last_update_submitted_qc>December 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>Rolf Karlsten</name_title>
    <organization>AstraZeneca R&amp;D Södertälje</organization>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>safety</keyword>
  <keyword>chronic low back pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

